TY - JOUR
T1 - Machine Learning Adds to Clinical and CAC Assessments in Predicting 10-Year CHD and CVD Deaths
AU - Nakanishi, Rine
AU - Slomka, Piotr J.
AU - Rios, Richard
AU - Betancur, Julian
AU - Blaha, Michael J.
AU - Nasir, Khurram
AU - Miedema, Michael D.
AU - Rumberger, John A.
AU - Gransar, Heidi
AU - Shaw, Leslee J.
AU - Rozanski, Alan
AU - Budoff, Matthew J.
AU - Berman, Daniel S.
N1 - Funding Information:
This research was supported in part by grant R01HL089765 from the National Heart, Lung, and Blood Institute/National Institutes of Health (Piotr J. Slomka, principal investigator). Dr. Blaha has received support from National Institutes of Health award L30 HL 110027 for this project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. At Cedars-Sinai, the study was supported in part by a grant from the Miriam & Sheldon G. Adelson Medical Research Foundation (Daniel S. Berman, principal investigator). Dr. Budoff has served as a consultant for General Electric. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/3
Y1 - 2021/3
N2 - Objectives: The aim of this study was to evaluate whether machine learning (ML) of noncontrast computed tomographic (CT) and clinical variables improves the prediction of atherosclerotic cardiovascular disease (ASCVD) and coronary heart disease (CHD) deaths compared with coronary artery calcium (CAC) Agatston scoring and clinical data. Background: The CAC score provides a measure of the global burden of coronary atherosclerosis, and its long-term prognostic utility has been consistently shown to have incremental value over clinical risk assessment. However, current approaches fail to integrate all available CT and clinical variables for comprehensive risk assessment. Methods: The study included data from 66,636 asymptomatic subjects (mean age 54 ± 11 years, 67% men) without established ASCVD undergoing CAC scanning and followed for cardiovascular disease (CVD) and CHD deaths at 10 years. Clinical risk assessment incorporated the ASCVD risk score. For ML, an ensemble boosting approach was used to fit a predictive classifier for outcomes, followed by automated feature selection using information gain ratio. The model-building process incorporated all available clinical and CT data, including the CAC score; the number, volume, and density of CAC plaques; and extracoronary scores; comprising a total of 77 variables. The overall proposed model (ML all) was evaluated using a 10-fold cross-validation framework on the population data and area under the curve (AUC) as metrics. The prediction performance was also compared with 2 traditional scores (ASCVD risk and CAC score) and 2 additional models that were trained using all the clinical data (ML clinical) and CT variables (ML CT). Results: The AUC by ML all (0.845) for predicting CVD death was superior compared with those obtained by ASCVD risk alone (0.821), CAC score alone (0.781), and ML CT alone (0.804) (p < 0.001 for all). Similarly, for predicting CHD death, AUC by ML all (0.860) was superior to the other analyses (0.835 for ASCVD risk, 0.816 for CAC, and 0.827 for ML CT; p < 0.001). Conclusions: The comprehensive ML model was superior to ASCVD risk, CAC score, and an ML model fitted using CT variables alone in the prediction of both CVD and CHD death.
AB - Objectives: The aim of this study was to evaluate whether machine learning (ML) of noncontrast computed tomographic (CT) and clinical variables improves the prediction of atherosclerotic cardiovascular disease (ASCVD) and coronary heart disease (CHD) deaths compared with coronary artery calcium (CAC) Agatston scoring and clinical data. Background: The CAC score provides a measure of the global burden of coronary atherosclerosis, and its long-term prognostic utility has been consistently shown to have incremental value over clinical risk assessment. However, current approaches fail to integrate all available CT and clinical variables for comprehensive risk assessment. Methods: The study included data from 66,636 asymptomatic subjects (mean age 54 ± 11 years, 67% men) without established ASCVD undergoing CAC scanning and followed for cardiovascular disease (CVD) and CHD deaths at 10 years. Clinical risk assessment incorporated the ASCVD risk score. For ML, an ensemble boosting approach was used to fit a predictive classifier for outcomes, followed by automated feature selection using information gain ratio. The model-building process incorporated all available clinical and CT data, including the CAC score; the number, volume, and density of CAC plaques; and extracoronary scores; comprising a total of 77 variables. The overall proposed model (ML all) was evaluated using a 10-fold cross-validation framework on the population data and area under the curve (AUC) as metrics. The prediction performance was also compared with 2 traditional scores (ASCVD risk and CAC score) and 2 additional models that were trained using all the clinical data (ML clinical) and CT variables (ML CT). Results: The AUC by ML all (0.845) for predicting CVD death was superior compared with those obtained by ASCVD risk alone (0.821), CAC score alone (0.781), and ML CT alone (0.804) (p < 0.001 for all). Similarly, for predicting CHD death, AUC by ML all (0.860) was superior to the other analyses (0.835 for ASCVD risk, 0.816 for CAC, and 0.827 for ML CT; p < 0.001). Conclusions: The comprehensive ML model was superior to ASCVD risk, CAC score, and an ML model fitted using CT variables alone in the prediction of both CVD and CHD death.
KW - cardiovascular disease death
KW - coronary artery calcification
KW - coronary heart disease death
KW - machine learning
KW - pooled cohort equation
UR - http://www.scopus.com/inward/record.url?scp=85097065304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097065304&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2020.08.024
DO - 10.1016/j.jcmg.2020.08.024
M3 - Article
C2 - 33129741
AN - SCOPUS:85097065304
SN - 1936-878X
VL - 14
SP - 615
EP - 625
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 3
ER -